Clinical Trials Logo
  1. Home
  2. Alport Syndrome
  3. NCT06425055

Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) — ALPESTRIA-1  

Alport Syndrome Clinical Trial

Official title:
Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome

Clinical Trial Summary

This study is a proof-of-concept trial of vonafexor safety, its effects on kidney function in subjects with at risk of progression Alport syndrome.

Clinical Trial Description

This is a multicenter study and several clinical sites and countries will be involved. This single arm, fixed dose escalation, open-label, non-randomized study will evaluate three dose levels of vonafexor on safety, tolerability and their effect on kidney function and renal biomarkers in 20 patients with AS at risk of progression. The total duration of study for a participant will be up to 40 weeks and include a screening period, a treatment period of 24 weeks and a follow-up period of 12 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06425055
Study type Interventional
Source Enyo Pharma
Contact Isabelle Martin
Phone +33 4 37 70 02 44
Email clinicaltrial@enyopharma.com
Status Recruiting
Phase Phase 2
Start date June 6, 2024
Completion date October 13, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT01696253 - Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Terminated NCT01602835 - Human Urine Sample Collection for Alport Nephropathy Biomarker Studies N/A
Recruiting NCT00481130 - Alport Syndrome Treatments and Outcomes Registry
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT05448755 - A Study of ELX-02 in Patients With Alport Syndrome Phase 2
Recruiting NCT06274489 - A Study to Evaluate Setanaxib in Patients With Alport Syndrome Phase 1/Phase 2
Terminated NCT02855268 - Study of Lademirsen (SAR339375) in Patients With Alport Syndrome Phase 2
Recruiting NCT06226896 - Effects of Dapagliflozin on Progression of Alport Syndrome
Recruiting NCT05927467 - Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
Terminated NCT03749447 - An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) Phase 3
Completed NCT03019185 - A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL Phase 2/Phase 3
Completed NCT01705132 - Urinary Biomarkers of the Progression of Alport Kidney Disease N/A
Recruiting NCT05267262 - Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis Phase 2
Completed NCT00622544 - A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
Recruiting NCT02378805 - European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Not yet recruiting NCT05655728 - Treatment With Metformin in Chinese Children With Alport Syndrome Phase 4
Completed NCT00309257 - Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome Phase 2
Not yet recruiting NCT05133050 - Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants N/A
Recruiting NCT04947813 - Genotype-Phenotype Correlations in Patients With Alport Syndrome